Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Heier Jeffrey S. | Chief Scientific Officer | Nov 25 '24 | Sale | 9.01 | 2,948 | 26,561 | 269,059 | Nov 27 07:52 AM | Kaiser Peter | Chief Development Officer | Nov 25 '24 | Sale | 9.01 | 2,897 | 26,102 | 213,087 | Nov 27 07:51 AM | Nayak Sanjay | Chief Strategy Officer | Nov 25 '24 | Sale | 9.00 | 1,814 | 16,326 | 174,380 | Nov 27 07:49 AM | Dugel Pravin | See Remarks | Nov 25 '24 | Sale | 9.01 | 20,680 | 186,327 | 791,793 | Nov 27 07:47 AM | SANJAY NAYAK | Officer | Nov 25 '24 | Proposed Sale | 8.97 | 1,814 | 16,273 | | Nov 25 06:42 PM | PETER KAZUO KAISER | Officer | Nov 25 '24 | Proposed Sale | 9.01 | 2,897 | 26,095 | | Nov 25 06:23 PM | PRAVIN DUGEL | Officer | Nov 25 '24 | Proposed Sale | 9.01 | 17,783 | 160,186 | | Nov 25 06:19 PM | PRAVIN DUGEL | Officer | Nov 25 '24 | Proposed Sale | 9.01 | 2,897 | 26,095 | | Nov 25 05:44 PM | JEFFREY S. HEIER | Officer | Nov 25 '24 | Proposed Sale | 9.01 | 2,948 | 26,550 | | Nov 25 05:10 PM | PHILIP C. STRASSBURGER | Officer | Oct 16 '24 | Proposed Sale | 10.23 | 13,125 | 134,269 | | Oct 16 04:25 PM | Nayak Sanjay | Chief Strategy Officer | Aug 23 '24 | Sale | 9.02 | 1,832 | 16,525 | 176,194 | Aug 27 05:19 PM | Dugel Pravin | See Remarks | Aug 23 '24 | Sale | 9.02 | 20,880 | 188,338 | 812,473 | Aug 27 05:17 PM | RABIA OZDEN | Officer | Aug 27 '24 | Proposed Sale | 9.00 | 18,333 | 164,997 | | Aug 27 04:18 PM | PRAVIN DUGEL | Officer | Aug 23 '24 | Proposed Sale | 9.02 | 20,880 | 188,271 | | Aug 23 05:10 PM | SANJAY NAYAK | Officer | Aug 23 '24 | Proposed Sale | 9.02 | 1,832 | 16,526 | | Aug 23 04:36 PM | RABIA OZDEN | Officer | Aug 21 '24 | Proposed Sale | 8.90 | 10,000 | 89,047 | | Aug 21 05:32 PM | RABIA OZDEN | Officer | Aug 07 '24 | Proposed Sale | 8.50 | 15,000 | 127,500 | | Aug 07 04:15 PM | ANTONY MATTESSICH | Former Officer | Aug 01 '24 | Proposed Sale | 8.19 | 23,979 | 196,498 | | Aug 01 04:30 PM | LINDSTROM RICHARD L MD | Director | Feb 27 '24 | Option Exercise | 8.80 | 30,302 | 266,658 | 150,704 | Jul 26 07:30 PM | Nayak Sanjay | Chief Strategy Officer | May 23 '24 | Sale | 5.84 | 2,274 | 13,280 | 178,026 | May 28 05:01 PM | Dugel Pravin | See Remarks | May 23 '24 | Sale | 5.79 | 21,626 | 125,215 | 833,353 | May 28 05:00 PM | SUMMER ROAD LLC | 10% Owner | Feb 26 '24 | Buy | 7.52 | 930,851 | 7,000,000 | 8,591,401 | Feb 27 04:43 PM | Notman Donald | Chief Financial Officer | Jan 31 '24 | Sale | 4.95 | 6,433 | 31,843 | 139,932 | Feb 02 07:03 PM | Ozden Rabia Gurses | Chief Medical Officer | Jan 31 '24 | Sale | 4.95 | 7,764 | 38,432 | 92,767 | Feb 02 07:02 PM | Strassburger Philip C. | General Counsel | Jan 31 '24 | Sale | 4.95 | 6,831 | 33,813 | 109,218 | Feb 02 07:01 PM | White Christopher G | Chief Business Officer | Jan 31 '24 | Sale | 4.95 | 5,147 | 25,478 | 89,619 | Feb 02 07:01 PM | Mattessich Antony C. | President and CEO | Jan 31 '24 | Sale | 4.95 | 18,338 | 90,773 | 427,943 | Feb 02 07:00 PM | SUMMER ROAD LLC | 10% Owner | Dec 14 '23 | Buy | 3.25 | 1,538,461 | 4,999,998 | 7,660,550 | Dec 18 04:52 PM |
|